Mast Therapeutics (NASDAQ:SVRA) Lowered to “Buy” at BidaskClub

Mast Therapeutics (NASDAQ:SVRA) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday, January 9th.

A number of other brokerages also recently issued reports on SVRA. JMP Securities started coverage on Mast Therapeutics in a report on Monday, September 11th. They set an “outperform” rating and a $20.00 price target on the stock. Roth Capital reduced their price target on Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, October 31st. Canaccord Genuity boosted their price target on Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 30th. ValuEngine downgraded Mast Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research downgraded Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Mast Therapeutics has an average rating of “Buy” and an average price target of $23.58.

Shares of Mast Therapeutics (NASDAQ SVRA) opened at $13.05 on Tuesday. Mast Therapeutics has a 52 week low of $4.60 and a 52 week high of $17.19. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15. The stock has a market capitalization of $398.03, a PE ratio of -3.12 and a beta of 0.18.

Mast Therapeutics (NASDAQ:SVRA) last released its earnings results on Wednesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.12. sell-side analysts forecast that Mast Therapeutics will post -1.64 EPS for the current year.

In related news, Director Yuri Pikover purchased 50,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were bought at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the purchase, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $1,177,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by BBNS and is owned by of BBNS. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/bidaskclub-lowers-mast-therapeutics-svra-to-buy/1819775.html.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.